Antihistamines are widely used to treat allergic diseases; these drugs plasma concentration reaches a peak in a relatively short time, counteracting the allergy's acute effects. Considering the chronicity of some symptoms, the effect of the antihistamine has to be prolonged over time; therefore, it is important to propose controlled-release systems. Supercritical Antisolvent coprecipitation is used to process cetirizine dihydrochloride and ketotifen, two antihistamines, using zein as the carrier to obtain controlled-release systems. The effect of temperature and polymer/drug ratio on the morphology and mean size of the powders is evaluated. From the UV–vis drug dissolution tests, it is possible to observe that the release of the active ingredient is significantly prolonged for both the antihistamines. Thanks to the presence of an initial burst effect, last generation formulations with bimodal releases are obtained, which allow to offer immediate relief from allergic symptoms followed by a prolonged release of the active ingredient.

Controlled-release antihistamines using supercritical antisolvent process

Franco P.;De Marco I.
2021

Abstract

Antihistamines are widely used to treat allergic diseases; these drugs plasma concentration reaches a peak in a relatively short time, counteracting the allergy's acute effects. Considering the chronicity of some symptoms, the effect of the antihistamine has to be prolonged over time; therefore, it is important to propose controlled-release systems. Supercritical Antisolvent coprecipitation is used to process cetirizine dihydrochloride and ketotifen, two antihistamines, using zein as the carrier to obtain controlled-release systems. The effect of temperature and polymer/drug ratio on the morphology and mean size of the powders is evaluated. From the UV–vis drug dissolution tests, it is possible to observe that the release of the active ingredient is significantly prolonged for both the antihistamines. Thanks to the presence of an initial burst effect, last generation formulations with bimodal releases are obtained, which allow to offer immediate relief from allergic symptoms followed by a prolonged release of the active ingredient.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11386/4769653
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact